In a world where we are starved of research, an absence of small cap coverage is an obvious externality of banning commission based payments…is it so bad for corporates to pay for coverage themselves?
The issue of paid research and its potential impact on the availability and quality of coverage for small-cap companies is a complex one, and it involves various perspectives and considerations. Let’s break down the main points:
- Absence of Small-Cap Coverage: Banning commission-based payments may lead to a reduction in research coverage for small-cap companies. These smaller companies may struggle to attract attention from research analysts without compensation. As a result, investors may have limited information and analysis to make informed decisions about these companies.
- Quality of Paid Research: Some argue that paid research, like that provided by companies such as Edison or Quoted Data, can be of high quality and thorough. These research providers are transparent about their relationships with the companies they cover and offer valuable insights to investors. Unlike certain brokers who may engage in biased analysis due to conflicts of interest, reputable research firms often maintain higher standards.
- Conflict of Interest and Transparency: The critical factor in paid research is transparency. As long as it is explicitly disclosed that the research is commissioned and paid for by the companies being covered, readers can take that into account when assessing the information. The issue arises when there is a lack of transparency, and readers are not aware of the potential biases or conflicts of interest.
- Unethical Practices: Some stock commentators or “wideboys” may engage in unethical practices, such as pumping and dumping stocks for personal gain. These practices can mislead and harm investors, leading to financial losses.
- Importance of Research to Investors: Research is vital for investors, especially in the case of small-cap companies where information may be scarce. Paid research can fill the gap and provide investors with valuable insights, but it is essential to differentiate between objective analysis and promotional material.
- Balancing Interests: On one hand, paid research can serve as a source of information and analysis for investors. On the other hand, it is crucial to ensure that readers are aware of the financial relationships between the research provider and the covered companies to make informed decisions.
- Potential Impact on Revenue: Companies may engage in paid research to promote themselves and increase revenue, especially if they lack other sources of income like transaction revenue or merger and acquisition opportunities.
I’ve no problem with quality paid for research from the likes of Edison. It’s no different to brokers plugging the shares of Companies that pay them. Often Edison and others (e.g Quoted Data) are far more thorough than the average broker note. And unlike some Brokers Edison doesn’t hide negatives either.
If you download a regulated broker note it always contains a very clear disclaimer at the end. For instance with ‘Equity Development Limited’ research you get this:
‘Equity Development Limited (‘ED’) is retained to act as financial adviser for its corporate clients, some or all of whom may now or in the future have an interest in the contents of this document. ED produces and distributes research for these corporate clients to persons who are not clients of ED. In the preparation of this report ED has taken professional efforts to ensure that the facts stated herein are clear, fair and not misleading, but makes no guarantee as to the accuracy or completeness of the information or opinions contained herein.’
There is no subterfuge intended. They are paid for research. That’s clear. They provide detailed notes and facts on companies…often giving colour on issues that can’t be made so easily in regulated rns statements. Of course, they will never issue a note saying sell sell sell.
They are FCA regulated. This means people at Equity Development Limited are not allowed to front run their own recommendations…if they personally own any stocks that they recommend through their paid for service there will be significant controls on how they do that (when they can buy, when they can sell, how long they must hold for and no short term trading). Ie, they ain’t going to pump and dump on you! They probably aren’t allowed to buy a stock between time of initial engagement discussion and their first research note for example. And they won’t be allowed to sell on any sneaky inside news. I’ve been in a similar environment. Its onerous. A dodgy operator may always seek a way round the rules…but at v high personal risk
There are many other stock commentators about that don’t operate with such high ‘cleansing’ standards though. I’m not gonna name names as many people here love those pump and dump stock cads and lose their sheet if I say anything about them. These wideboy stock commentators give low to zero analysis and are clearly touting their own holdings after they have built a position….they are using you, yet many of you seem more okay about this than paid for detailed research. They definitely wont tell you they are going to sell either…they’ll sell and then maybe tell you…perhaps they will even put a short on to milk extra return from you.
IMO the above wideboys are pretty despicable. They use you and profit from you. You think they give you something but really they are just confidence tricksters…knowing that they can play on your uncertainty and anxiety for their gain.
But in the end we need more research to private investors not less, who cares what any brokers target price or fair value is, personally I never pay this any attention… It’s an individual judgement based on so many variables.
Transparency Matters: The Case for Clear Disclosure in Paid Research
I do not see an issue at all with paid research being published anywhere. All research is aimed at increasing revenue to the publisher…normally transaction revenue…normally corporate Merger and Acquisitions of some sort. So in the absence of potential deal flow perhaps we should expect more companies to publish paid research. They are being paid to promote companies to personal investors. On the other hand, they are providing a service with the information about companies that might not otherwise be available, and potentially more contact from management. I suppose you get what you pay for…
personally I find them very useful, especially where we don’t have access to notes from other brokers. Although as you say, the “opinions” and price targets have to be seen for what they are – commissioned PR.
However it simply needs to be clear. Exactly the same as “advertorials” that are very clearly (and legally required) to be highlighted when newspapers write pieces. I don’t believe readers here should have to “guess” or be expected to know “of course it’s paid research” or even then have to fall back on the DYOR trick.
In conclusion, paid research can be a valuable source of information for investors, especially in the case of small-cap companies with limited coverage from traditional research analysts. However, transparency is crucial to ensure readers are aware of the financial relationships between the research provider and the companies being covered. As long as the information is presented openly and without subterfuge, investors can use it as one of many tools in their decision-making process. The challenge lies in addressing unethical practices and maintaining high standards of transparency and integrity in the dissemination of research information.
